Dynamic estimates of survival of patients with poorly differentiated thyroid carcinoma: a population-based study

被引:0
|
作者
Liu, Zhao [1 ]
Xu, Qianlan [2 ]
Xia, Heng [1 ]
Wang, Miaofeng [1 ]
机构
[1] Shaoxing Univ, Shaoxing Cent Hosp, Cent Affiliated Hosp, Dept Breast & Thyroid Surg, Shaoxing, Peoples R China
[2] Shaoxing Univ, Shaoxing Cent Hosp, Cent Affiliated Hosp, Dept Gynecol, Shaoxing, Peoples R China
来源
关键词
poorly differentiated thyroid carcinoma; SEER; prognosis; conditional survival; nomogram; CONDITIONAL SURVIVAL; PROGNOSTIC-FACTORS;
D O I
10.3389/fendo.2024.1375274
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The real-time prognostic data of patients with poorly differentiated thyroid carcinoma (PDTC) after surviving for several years was unclear. This study aimed to employ a novel method to dynamically estimate survival for PDTC patients.Methods A total of 913 patients diagnosed with PDTC between 2014 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database, was recruited in our study. Kaplan-Meier method was used to estimate the overall survival (OS). The conditional survival (CS) outcomes of PDTC were analyzed and CS rates were calculated using the formula CS(y/x) = OS(y+x)/OS(x), whereby CS(y/x) denotes the probability of a patient enduring an additional y years subsequent to surviving x years following the diagnosis of PDTC. The least absolute shrinkage and selection operator (LASSO) regression was employed to identify prognostic predicters and multivariate Cox regression was utilized to develop a CS-nomogram. Finally, the performance of this model was evaluated and validated.Results Kaplan-Meier survival analysis unveiled patient outcomes demonstrating an OS rate of 83%, 75%, and 60% respectively at the end of 3, 5, and 10 years. The novel CS analysis highlighted a progressive enhancement in survival over time, with the 10-year cumulative survival rate progressively augmenting from its initiation of 60% to 66%, 69%, 73%, 77%, 81%, 83%, 88%, 93%, and finally 97% (after surviving for 1-9 years, respectively) each year. And then 11 (11/15) predictors including age at diagnosis, sex, histology type, SEER stage, T stage, N stage, M stage, tumor size, coexistence with other malignancy, radiotherapy and marital status, were selected by LASSO analysis under the condition of lambda.min. Multivariate Cox regression analysis further highlighted the significant impact of all these predictors on the OS of PDTC and we successfully established and validated a novel CS-nomogram for real-time and dynamic survival prediction.Conclusions This was the first study to analyze the CS pattern and demonstrate a gradual improvement in CS over time in long-term PDTC survivors. We then successfully developed and validated a novel CS-nomogram for individualized, dynamic, and real-time survival forecasting, empowering clinicians to adapt and refine the patient-tailored treatment strategy promptly with consideration of evolving risks.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Postoperative radioiodine therapy impact on survival in poorly differentiated thyroid carcinoma: a population-based study
    Xu, Lei
    Zou, Qiong
    Jiao, Ju
    Zhang, Yong
    NUCLEAR MEDICINE COMMUNICATIONS, 2022, 43 (02) : 145 - 151
  • [2] A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma
    Bhattacharyya, N
    OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2003, 128 (01) : 115 - 123
  • [3] Prognostic nomogram models for elderly patients with differentiated thyroid carcinoma: A population-based study
    Wang, Dasong
    Yang, Yan
    Yang, Hongwei
    He, Yu
    Wang, Zhengyan
    Chen, Maoshan
    Huang, Yunhui
    Yang, Lei
    MEDICINE, 2024, 103 (44)
  • [4] Survival Prognostication in Patients with Differentiated Thyroid Cancer and Distant Metastases: A SEER Population-Based Study
    Chen, Debbie W.
    Carr, Grant
    Worden, Francis P.
    Veenstra, Christine M.
    Haymart, Megan R.
    Banerjee, Mousumi
    THYROID, 2024, 34 (07) : 837 - 845
  • [5] Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference?
    Bichoo, Raouef Ahmed
    Mishra, Anjali
    Kumari, Niraj
    Krishnani, Narendra
    Chand, Gyan
    Agarwal, Gaurav
    Agarwal, Amit
    Mishra, Saroj Kanta
    LANGENBECKS ARCHIVES OF SURGERY, 2019, 404 (01) : 45 - 53
  • [6] Poorly differentiated thyroid carcinoma and poorly differentiated area in differentiated thyroid carcinoma: is there any difference?
    Raouef Ahmed Bichoo
    Anjali Mishra
    Niraj Kumari
    Narendra Krishnani
    Gyan Chand
    Gaurav Agarwal
    Amit Agarwal
    Saroj Kanta Mishra
    Langenbeck's Archives of Surgery, 2019, 404 : 45 - 53
  • [7] Outcomes in Patients With Poorly Differentiated Thyroid Carcinoma
    Ibrahimpasic, T.
    Ghossein, R.
    Carlson, D. L.
    Nixon, I.
    Palmer, F. L.
    Shaha, A. R.
    Patel, S. G.
    Tuttle, R. M.
    Shah, J. P.
    Ganly, I.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (04): : 1245 - 1252
  • [8] Poorly differentiated thyroid carcinoma: a clinicopathological study
    Johari, M.
    Rabade, K.
    Rane, S.
    Mittal, N.
    Bal, M.
    Patil, A.
    VIRCHOWS ARCHIV, 2024, 485 : S125 - S125
  • [9] Poorly Differentiated Thyroid Carcinoma
    Bongiovanni, Massimo
    Faquin, William C.
    BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: DEFINITIONS, CRITERIA AND EXPLANATORY NOTES, 2010, : 129 - +
  • [10] Poorly differentiated thyroid carcinoma
    Xu, Bin
    Ghossein, Ronald
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2020, 37 (05) : 243 - 247